Introduction: From Fingersticks to Continuous Insight

For decades, managing type 1 diabetes (T1D) meant punctuating daily life with fingerstick blood tests—pricking a fingertip, applying a strip, reading a number, and acting on that single moment’s snapshot. While that approach has saved countless lives, it offers only intermittent data and leaves significant gaps in understanding what happens between tests. Fatigue, overnight drops, post-meal spikes, and the subtle drift of glucose during exercise often go unnoticed until symptoms appear. The result is a constant guessing game that pushes many people with T1D toward burnout and increases the risk of long-term complications.

Now, a new generation of wearable biosensors is rewriting that narrative. Supported by organizations like JDRF (the Juvenile Diabetes Research Foundation), these devices offer the promise of continuous, real-time physiological monitoring without the need for repeated blood sampling. Continuous glucose monitoring (CGM) systems are the most visible success story, but the landscape is rapidly expanding to include non-invasive optical sensors, sweat-based analyzers, and even multi-analyte patches that track ketones, lactate, and other biomarkers alongside glucose. This article explores how JDRF has been a driving force behind these innovations, the concrete benefits they deliver, the challenges that remain, and the exciting frontiers on the horizon.

Understanding Wearable Biosensors: How They Work and What They Measure

Wearable biosensors are compact electronic devices that adhere to the skin and measure physiological parameters continuously or at frequent intervals. In the context of T1D, the dominant type is the electrochemical continuous glucose monitor (CGM), which uses a thin, flexible filament inserted just under the skin—typically on the abdomen or back of the upper arm—and an enzymatic reaction (glucose oxidase) that produces an electrical current proportional to interstitial glucose concentration. That current is translated into a glucose reading, usually transmitted every one to five minutes to a smartphone or dedicated receiver.

Types of Wearable Biosensors for Diabetes

Beyond conventional CGMs, several emerging categories aim to reduce invasiveness and expand the range of tracked metrics:

  • Electrochemical CGM (the current standard): Examples include Dexcom G7, Abbott FreeStyle Libre, and Medtronic Guardian. Sensors last from 7 to 14 days and require minimal user intervention beyond initial insertion and periodic calibration for some models.
  • Optical / Fluorescence-based sensors: These use light to detect glucose changes in interstitial fluid or even through the skin. They are being explored as a way to avoid filament insertion entirely, though clinical accuracy remains a challenge.
  • Microneedle arrays: A patch of tiny, painless microneedles penetrates the outer skin layer to access interstitial fluid. These offer a middle ground between conventional CGM filaments and truly non-invasive methods.
  • Sweat-based and tear-based sensors: Researchers are developing devices that analyze glucose in sweat or tears, bypassing the need for direct interstitial access. While promising, consistency and lag time relative to blood glucose are still being addressed.

How Data Flows from Skin to Decision

Regardless of type, all wearable biosensors share a common pipeline: a sensor generates a signal, a transmitter sends that data wirelessly (e.g., via Bluetooth Low Energy), an algorithm filters and converts the signal into a glucose value, and the device displays the result—often with trend arrows and customizable alerts. Many systems now integrate directly with insulin pumps (creating sensor-augmented pump therapy) or with smartphone apps that log meals, activity, and insulin doses, enabling richer data analysis over time.

The Role of JDRF in Driving Innovation

JDRF has been a cornerstone of diabetes technology advancement for more than two decades. From early funding for the original artificial pancreas concepts to large-scale clinical trials that helped bring CGM into standard care, the organization’s strategic investments have accelerated the timeline from lab bench to real-world use. JDRF’s approach combines direct research funding, partnerships with device manufacturers, advocacy for regulatory pathways, and support for user-centered design.

Key Milestones Supported by JDRF

A few landmark achievements illustrate JDRF’s impact:

  • 2006–2008: JDRF launched the Artificial Pancreas Project, a multi-million-dollar initiative that funded pivotal studies on CGM accuracy and closed-loop algorithms. This effort directly influenced the design of early commercial systems like the Medtronic MiniMed 670G.
  • 2010–2015: JDRF supported the development and validation of “threshold suspend” technology—a feature that automatically stops insulin delivery when a CGM reading predicts an approaching low. This innovation reduced severe hypoglycemia events by over 50% in clinical trials.
  • 2016–2020: Through the JDRF-funded International Diabetes Closed Loop (iDCL) consortium, researchers demonstrated that hybrid closed-loop systems significantly improve time-in-range (TIR) compared to standard therapy, leading to wider insurance coverage and regulatory approvals.
  • 2022–present: JDRF is investing in next-generation biosensor research, including stretchable electronics, biostable enzyme coatings, and non-invasive optical sensing, with the goal of extending sensor wear duration beyond 14 days and eliminating calibration needs entirely.

Beyond hardware, JDRF has also funded large-scale registry studies (like T1D Exchange) that collect real-world CGM data to refine clinical recommendations and demonstrate long-term value to payers and policymakers.

Clinical Benefits of Continuous Monitoring

The move from intermittent fingersticks to continuous monitoring has produced measurable improvements in glycemic outcomes, quality of life, and complication risk. These benefits are not merely theoretical; they are backed by robust evidence from randomized controlled trials and meta-analyses.

Improved Glycemic Control and Time-in-Range

The most direct benefit is an increase in time spent within the target glucose range (70–180 mg/dL). Multiple studies show that CGM users achieve 3–6 percentage points higher TIR compared to those using fingerstick-only methods. That translates to roughly one to two additional hours per day in a safe zone. For individuals using automated insulin delivery systems that integrate CGM data, TIR gains can be even larger—approaching 70–80% for those who start with lower baseline control.

Reduced Hypoglycemia and Fear of Lows

Hypoglycemia—especially nocturnal or severe hypos that require third-party assistance—is one of the most dangerous T1D complications. Wearable biosensors with predictive low-glucose alerts give users a 20–30 minute warning, allowing them to act before symptoms set in. JDRF-funded research has shown that such alerts reduce severe hypoglycemia by up to 50% in high-risk populations. Equally important is the psychological benefit: the constant worry about lows diminishes when a device provides a safety net, enabling better sleep, exercise, and spontaneous daily activities.

Reduction in Fingersticks and Procedural Burden

Before CGM, people with T1D performed an average of 6–10 fingersticks per day. Many reported that the pain, cost, and hassle of testing led to skipped or ignored readings. Modern CGMs require only one fingerstick (for calibration) every 12–24 hours, and some factory-calibrated systems (like the Dexcom G7 and FreeStyle Libre 3) require no fingerstick calibration at all. This reduction in invasive testing has been shown to improve adherence and reduce diabetes distress—a well-documented contributor to poor outcomes.

Continuous monitoring generates a wealth of data that helps clinicians and users identify patterns. Ambulatory glucose profiles (AGPs) and daily trend graphs reveal how meals, exercise, stress, and even menstrual cycles affect glucose. Armed with this information, endocrinologists can fine-tune insulin-to-carb ratios, basal rates, and correction factors far more accurately than with episodic fingerstick data. JDRF has supported development of data visualization tools and machine learning platforms that aggregate CGM data across populations to identify best practices.

Remaining Challenges: Accuracy, Durability, and Access

Despite remarkable progress, wearable biosensors are not yet perfect. Understanding these limitations is essential for realistic expectations and for guiding future innovation.

Accuracy and the Lag Problem

Interstitial glucose lags behind blood glucose by 5–15 minutes, especially during rapid changes (e.g., after a meal or during exercise). This lag can cause CGMs to underestimate high peaks or miss the depth of a low trough. While algorithms continue to improve, manufacturers typically report mean absolute relative difference (MARD) values around 8–10%. For users near the edges of target range, that margin can still lead to false alarms or missed alerts.

Sensor Longevity and Skin Irritation

Most wearable biosensors are approved for 7–14 days of wear. Prolonged use often triggers skin reactions—redness, itching, even contact dermatitis from the adhesive or the sensor material itself. JDRF is funding research into hypoallergenic adhesives and thinner, more flexible substrates that reduce mechanical irritation. However, until wear duration extends to three or four weeks, users must manage the hassle of frequent replacements and the risk of sensor failure during the night.

Cost and Insurance Coverage

Even with broad insurance coverage in many high-income countries, out-of-pocket costs for CGM systems remain a barrier. In the United States, commercial deductibles, copays, and gaps in coverage for older adults on Medicare can make annual costs exceed $2,000. JDRF actively advocates for policies that reduce patient costs and for inclusion of CGM in essential health benefits. Global access is even more uneven; in low- and middle-income countries, fingerstick testing still dominates due to the upfront cost of sensors and transmitters.

Future Directions: Non-Invasive Sensors, AI, and the Closed Loop

The next five years promise dramatic advances that could make wearable biosensors even more seamless, predictive, and informative. JDRF’s current research portfolio targets three major frontiers: eliminating the need for any skin penetration, embedding intelligence directly into the sensor, and fully closing the loop between sensing and insulin delivery.

Breakthroughs in Non-Invasive Sensing

Truly non-invasive glucose monitoring—meaning no filament, no microneedle, no skin breach—has been a holy grail for decades. Recent progress in optical spectroscopy (near-infrared, Raman) and bioimpedance has renewed optimism. Startups and academic labs supported by JDRF are testing wristband-style devices that shine light through the skin and measure changes in glucose concentration from reflected or absorbed light. Challenges remain with motion artifacts, sweat interference, and calibration drift, but early pilot data suggest that non-invasive readings for day-to-day trends, if not real-time accuracy, are feasible within three to five years.

AI and Machine Learning for Prediction

Current CGMs display historical and current data; future systems will increasingly offer predictive guidance. Machine learning models trained on millions of hours of CGM data can forecast glucose values 30 to 60 minutes ahead with high accuracy. JDRF-funded projects are integrating these models directly into CGM apps, so a user sees not just the current glucose level but a “glucose forecast” that suggests what’s coming. Such predictions could enable proactive dosing adjustments and even automated preventive actions, such as raising basal insulin while still within the safe range to blunt an anticipated post-meal spike.

Multi-Analyte Sensors: Beyond Glucose

Type 1 diabetes management involves more than just glucose. Ketones, lactate, creatinine, and electrolyte levels all influence treatment decisions, especially during illness or diabetic ketoacidosis (DKA). JDRF is supporting the development of wearable patches that measure glucose and ketones simultaneously. Having a continuous ketone readout could reduce DKA hospitalizations by providing early warnings long before symptoms develop. Similarly, lactate monitoring is valuable for athletes and during illness to detect tissue hypoxia. These multi-analyte systems are still in early prototype stages but represent a logical extension of the CGM concept.

Full Closed Loop: The Artificial Pancreas, Next Generation

While hybrid closed-loop systems (like the Tandem Control-IQ and Medtronic 780G) already automate basal insulin adjustments, they still require user-initiated meal boluses. JDRF is investing in fully automated closed-loop systems that handle both basal and bolus insulin without user input. Achieving this requires ultra-reliable biosensors that can predict glycemic excursions with near-perfect accuracy and algorithms that can communicate with dual-hormone pumps (insulin plus glucagon) to prevent both highs and lows. A fully closed loop would be a transformative step toward “smart” diabetes management—almost effortless for the user.

Regulatory and Market Landscape

The path from prototype to clinic is shaped by regulatory oversight, reimbursement policies, and commercial competition. In the United States, the FDA reviews CGM systems as class II medical devices. JDRF has worked with the FDA to create clear guidance for new products, including specific acceptable MARD thresholds and safety requirements for automated insulin delivery systems. Similar efforts are underway with the European Medicines Agency and other global bodies to harmonize standards.

Currently, four major players dominate the CGM market: Dexcom, Abbott, Medtronic, and (in some regions) Senseonics. New entrants like Pacific Diabetes Technologies and Biolinq are developing next-gen biosensors that challenge existing form factors. JDRF’s role as an independent convener helps ensure that smaller innovators get access to funding, clinical trial infrastructure, and patient input.

Conclusion: The Path to a Brighter Future for T1D

Wearable biosensors have already transformed type 1 diabetes from a condition managed by isolated, reactive data points to one where continuous insight guides proactive decisions. The support of JDRF has been instrumental in shortening the gap between scientific discovery and patient benefit—funding fundamental sensor chemistry, promoting clinical validation, and advocating for coverage policies that put devices in the hands of those who need them most.

Looking ahead, the convergence of non-invasive sensing, predictive AI, and fully automated insulin delivery promises to lift the burden of minute-by-minute attention from people with T1D, allowing them to focus on life rather than on their glucose numbers. JDRF’s continued investment in biosensor innovation, paired with its commitment to affordability and global access, will determine how quickly that vision becomes reality. For the millions living with type 1 diabetes today—and for the next generation—the future of monitoring is continuous, comfortable, and finally keeping pace with the demands of life itself.